TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03034408
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01963754
Drug: Subperiosteal 1:100.000 Articaine 4% epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of subperiosteal anesthesia for implant placement
Study: NCT03843736
Drug: Probiotic Agent
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
Study: NCT00005848
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01244191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib Placebo tablets given twice a day
Study: NCT00862121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day orally, 2 g in the morning and 4 g in the evening
Study: NCT01338883
Drug: Sustiva + Truvada
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustiva plus Truvada
Study: NCT02555657
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00599027
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray once daily (two puffs per nostril) in the morning.
Study: NCT04214730
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will only receive Chemotherapy.
Study: NCT02067416
Drug: Anthracycline based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care neoadjuvant treatment with anthracycline based chemotherapy
Study: NCT01230749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
Study: NCT01769469
Drug: FTC/TDF (Truvada®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
Study: NCT02394795
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT02394795
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT02392494
Drug: MK-1075
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
Study: NCT01383967
Drug: LY2979165
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01383967
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00984880
Drug: AZD3043
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
Study: NCT00532428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02713789
Drug: hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02713789
Drug: Placebo (PBS-20% sucrose)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03789890
Drug: BAY1902607
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
Study: NCT04344379
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg per day
Study: NCT00131664
Drug: Avandia and Amaryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
Study: NCT00336778
Drug: 3TC, TDF, NLV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
Study: NCT04492878
Drug: IKERVIS®1mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of study medication once daily in each eye at bedtime during 90 days.
Study: NCT03541655
Drug: F14 (celecoxib)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib in novel drug delivery system (BEPO™)
Study: NCT04019652
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral administration; 10-mg or 40-mg dose
Study: NCT04019652
Drug: Placebo matching CS-3150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching CS-3150 tablets
Study: NCT01790009
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x500 mg Acetaminophen
Study: NCT02483078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02483078
Drug: Optimized Background Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
Study: NCT04178135
Drug: rLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH supplement from day 1 of stimulation
Study: NCT04178135
Drug: rLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH supplement from day 6 of stimulation
Study: NCT04470128
Drug: Stage I: HSK21542 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT04470128
Drug: Stage I: HSK21542 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT04470128
Drug: HSK21542 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT04470128
Drug: HSK21542 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT04470128
Drug: HSK21542 2 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT04470128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT01299610
Drug: GW870086 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to slightly colored opaque cream
Study: NCT01299610
Drug: GW870086 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to slightly colored opaque cream
Study: NCT01299610
Drug: FP 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: White cream
Study: NCT04255277
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenerimod matching placebo tablets will be administered once daily orally in the morning.
Study: NCT02963896
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
Study: NCT01975246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching hydrochlorothiazide tablet
Study: NCT03516955
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Superstat ® Tablets 10mg, 20mg
Study: NCT02919735
Drug: Placebo cutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
Study: NCT02581865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00855257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02862548
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally
Study: NCT03865511
Drug: TAGRISSO® 80mg (Osimertinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
Study: NCT01617655
Drug: Placebo (for alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Study: NCT01617655
Drug: Lipid Modifying Therapy (LMT)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT02897869
Drug: POL7080
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 doses of POL7080 alone over 2.5 days
Study: NCT02897869
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of Amikacin alone over 2.5 days
Study: NCT02897869
Drug: POL7080 + Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
Study: NCT04562558
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg intramuscularly on Days 1, 3, 5, 7 . Repeat every 14 days
Study: NCT04562558
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15mg intramuscularly on Days 2, 4, 6, 8. Repeat every 14 days
Study: NCT01965418
Drug: Fufang Biejia Ruangan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01965418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02621619
Drug: IV acetaminophen + 0.5 mg IV hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
Study: NCT03917225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
Study: NCT01332604
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral repeating dose
Study: NCT01332604
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00680953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
Study: NCT01081821
Drug: single dose NJ-39758979/ matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
Study: NCT03172481
Drug: PRC-063 oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose
Study: NCT03172481
Drug: Placebo oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose
Study: NCT01684683
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline 0.1 bid
Study: NCT01684683
Drug: Placebo(for Theophylline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
Study: NCT01705964
Drug: IM epinephrine 1:1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
Study: NCT00387348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo pill identical in appearance to the escitalpram pill once daily
Study: NCT00838461
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03342456
Drug: Doxycycline Hyclate Enteric-Coated Capsules
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: group 1,0.1g\*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
Study: NCT00382213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00292747
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00292747
Drug: Ibuprofen Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02468206
Drug: Lauromacrogol
Normalized name: Lauromacrogol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00502528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-interventional
Study: NCT02591888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
Study: NCT02521298
Drug: Cortico-Steroid Injection. Depomedrol 40mg/1ml.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02310906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP-4053 placebo-matching solution for IV infusion.
Study: NCT04164329
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
Study: NCT06177119
Drug: Placebos after SRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning after the last SRP session.
Study: NCT02119026
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance
Study: NCT02119026
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 bid d1-14,
Study: NCT00703469
Drug: MDX1106-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00703469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose
Study: NCT02022033
Drug: FOLFOXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)
Study: NCT01524237
Drug: LY2979165
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT02471911
Drug: KPT-330
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
Study: NCT01409993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo three times a day for three months
Study: NCT00141180
Drug: CP-481,715
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02994381
Drug: RPC1063
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01372449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01803711
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01803711
Drug: Placebo (for Omega 3 fatty acid supplement)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03746067
Drug: TS-134
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg, 10 mg, or 20 mg oral solution
Study: NCT03746067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo oral solution
Study: NCT04202549
Drug: intra-arterial cocktail therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
Study: NCT00185354
Drug: BAY86-5016, SH P00331F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
Study: NCT00002718
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01519401
Drug: 3 mg drospirenone and 20 µg ethinyl-estradiol
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01519401
Drug: 3 mg drospirenone and 30 µg ethinyl-estradiol
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00871572
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules by mouth taken once daily for 12 weeks
Study: NCT00871572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules by mouth once daily for 12 weeks
Study: NCT03165942
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02138396
Drug: Fentanyl Sublingual Spray (FSS)
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of fentanyl, 400 mcg per sublingual spray
Study: NCT02138396
Drug: Fentanyl Citrate Injection (FCI)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of fentanyl citrate, 100 mcg per intramuscular injection
Study: NCT01887106
Drug: GLPG1205 single ascending doses, oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
Study: NCT01887106
Drug: GLPG1205, multiple ascending doses, oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
Study: NCT01887106
Drug: Placebo, multiple ascending doses, oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses, daily for 14 days, oral suspension matching placebo
Study: NCT03071380
Drug: Repatoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 10 mg rivaroxaban
Study: NCT03846219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose.
Study: NCT04320290
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of DAA treatment
Study: NCT04066530
Drug: Mucosta tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosta tab. administered three times daily for two weeks
Study: NCT01684891
Drug: RG1662
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses of RG1662
Study: NCT02905903
Drug: Tricholoacetic Acid (TCA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
Study: NCT01705795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nacl four times over four months
Study: NCT02244281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00749450
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00749450
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03469232
Drug: Huanglian-Jiedu Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
Study: NCT02454933
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg q2w (IV) infusion
Study: NCT01565356
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 111 or 370MBq (3 or 10mCi), single dose
Study: NCT00721071
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
Study: NCT00055731
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03270839
Drug: Bonine 25Mg Chewable Tablet
Normalized name: BONINE 25mg Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion sickness drug
Study: NCT03270839
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active substance in the tablet
Study: NCT00425321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for up to 12 weeks
Study: NCT03927456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study: NCT02574598
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosing interval of pembrolizumab can be increased in case of toxicity.
Study: NCT04104178
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigating whether a significantly higher number of MRSA throat carriers succeed in becoming MRSA free, when using Clindamycin on top of our general recommended topical treatment of Mupirocin nasal ointment + chorhexidin baths
Study: NCT04104178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00324220
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD0103 Oral administration 3 times per week.